ArticleCancer medicine2021
A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
Article in Cancer medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 11 citations in OpenAlex.
- Molecular subtyping and prognostic modeling of colon adenocarcinoma based on programmed cell death features: a multi-omics and machine learning study.Frontiers in immunology · 2026Article
- Toward precision oncology in LUAD: a prognostic model using single-cell sequencing and WGCNA based on a disulfidptosis relative gene signature.Frontiers in immunology · 2025Article
- Unraveling the activation process and core driver genes of HSCs during cirrhosis by single-cell transcriptome.Experimental biology and medicine (Maywood, N.J.) · 2023Article
- Abandonment of intravenous volume expansion after preoperative receipt of α-blockers in patients with adrenal pheochromocytoma was not an independent risk factor for intraoperative hemodynamic instability.Frontiers in endocrinology · 2023Article
- FAM family gene prediction model reveals heterogeneity, stemness and immune microenvironment of UCEC.Frontiers in molecular biosciences · 2023Article
- Integrated analysis of single-cell and Bulk RNA sequencing reveals a malignancy-related signature in lung adenocarcinoma.Frontiers in oncology · 2023Article
- Integrating multiple machine learning methods to construct glutamine metabolism-related signatures in lung adenocarcinoma.Frontiers in endocrinology · 2023Article
- Constructing an immune- and ferroptosis-related lncRNA signature to predict the immune landscape of human bladder cancer.Journal of clinical laboratory analysis · 2022Article
- Comprehensive analysis of the endoplasmic reticulum stress-related long non-coding RNA in bladder cancer.Frontiers in oncology · 2022Article
- A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.Cancer medicine · 2021Article
- Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.Frontiers in molecular biosciences · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
backgroundBladder cancer is the second most common malignant tumor in the urogenital system. The research investigated the prognostic role of immune-related long non-coding RNA (lncRNA) in bladder cancer.
methodsWe extracted 411 bladder cancer samples from The Cancer Genome Atlas database. Single-sample gene set enrichment analysis was employed to assess the immune cell infiltration of these samples. We recognized differentially expressed lncRNAs between tumors and paracancerous tissues, and differentially expressed lncRNAs between the high and low immune cell infiltration groups. Venn diagram analysis detected differentially expressed lncRNAs that intersected the above groups. LncRNAs with prognostic significance were identified by regression analysis. Multivariate Cox analysis was used to establish the risk score model. Then we established and evaluated the nomogram. Additionally, we performed gene set enrichment analysis to explore the potential functions of the screened lncRNAs in tumor pathogenesis.
resultsThree hundred and twenty differentially expressed lncRNAs were recognized. We randomly divided patients into the training data set and the testing data set at a 2: 1 ratio. In the training data set, 9 immune-related lncRNAs with prognostic significance were identified. The risk score model was constructed to classify patients as high- and low-risk cohorts. Patients in the low-risk cohort had better survival outcomes than those in the high-risk cohort. The nomogram was established based on the indicators including age, gender, tumor-node-metastases stage, and risk score. The model's predictive performance was confirmed by the receiver operating characteristic curve analysis, concordance index method, calibration curve, and decision curve analysis. The testing data set also achieved similar results. Bioinformatics analysis suggested that the 9-lncRNA signature was involved in the modulation of various immune responses, antigen processing and presentation, and T cell receptor signaling pathway.
conclusionsOur study uncovered the prognostic value of immune-related lncRNAs for bladder cancer and showed that they may regulate tumor pathogenesis in various ways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.